ArticleMedical mycology2021
In vitro and in vivo interaction of caspofungin with isavuconazole against Candida auris planktonic cells and biofilms.
Article in Medical mycology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 31 citations in OpenAlex.
- Synergistic activity of caspofungin and posaconazole againstMicrobiology spectrum · 2026Article
- Evaluation of the Synergistic Activity of Anidulafungin with Isavuconazole, Voriconazole, Posaconazole, and Amphotericin B inInfection and drug resistance · 2026Article
- Xenosiderophore transporter gene expression and clade-specific filamentation in Candida auris killifish (Aphanius dispar) infection.Communications biology · 2025Article
- In vitro evidence to support amphotericin B and flucytosine combination therapy for talaromycosis.PLoS neglected tropical diseases · 2025Article
- Fast detection of synergy and antagonism in antifungal combinations used against Candida albicans clinical isolates.Scientific reports · 2025Article
- Innovative antifungal strategies to combat drug-resistantFrontiers in cellular and infection microbiology · 2025Review
- Review
- Isolate Specific Transcriptome Changes Exerted by Isavuconazole Treatment in Candida auris.Mycopathologia · 2024Article
- Efficacy of the combination of amphotericin B and echinocandins againstMicrobiology spectrum · 2024Article
- Heightened Efficacy of Anidulafungin When Used in Combination with Manogepix or 5-Flucytosine against Candida aurisAntimicrobial agents and chemotherapy · 2023Article
- PK/PD modeling and simulation of the in vitro activity of the combinations of isavuconazole with echinocandins against Candida auris.CPT: pharmacometrics & systems pharmacology · 2023Article
- Echinocandins - structure, mechanism of action and use in antifungal therapy.Journal of enzyme inhibition and medicinal chemistry · 2022Review
- Synergistic Interaction of Caspofungin Combined with Posaconazole againstAntibiotics (Basel, Switzerland) · 2022Article
- Small molecules for combating multidrug-resistant superbugActa pharmaceutica Sinica. B · 2022Review
- Evaluation of the Antimicrobial and Antivirulent Potential of Essential Oils Isolated fromMicroorganisms · 2022Article
- Antifungal Resistance and the Role of New Therapeutic Agents.Current infectious disease reports · 2022Review
- Therapeutic innovation for multi-resistant candidemics: Synergy of isavuconazole and caspofungin association.Hematology reports · 2021Article
- In Vitro Interaction and Killing-Kinetics of Amphotericin B Combined with Anidulafungin or Caspofungin againstPharmaceutics · 2021Article
- Comparison of In Vitro Killing Activity of Rezafungin, Anidulafungin, Caspofungin, and Micafungin against FourMicroorganisms · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 2 countries.
Funding
Abstract
The in vitro and in vivo efficacy of caspofungin was determined in combination with isavuconazole against Candida auris. Drug-drug interactions were assessed utilizing the fractional inhibitory concentration indices (FICIs), the Bliss independence model and an immunocompromised mouse model. Median planktonic minimum inhibitory concentrations (pMICs) of 23 C. auris isolates were between 0.5 and 2 mg/l and between 0.015 and 4 mg/l for caspofungin and isavuconazole, respectively. Median pMICs for caspofungin and isavuconazole in combination showed 2-128-fold and 2-256-fold decreases, respectively. Caspofungin and isavuconazole showed synergism in 14 out of 23 planktonic isolates (FICI range 0.03-0.5; Bliss cumulative synergy volume range 0-4.83). Median sessile MICs (sMIC) of 14 biofilm-forming isolates were between 32 and >32 mg/l and between 0.5 and >2 mg/l for caspofungin and isavuconazole, respectively. Median sMICs for caspofungin and isavuconazole in combination showed 0-128-fold and 0-512-fold decreases, respectively. Caspofungin and isavuconazole showed synergistic interaction in 12 out of 14 sessile isolates (FICI range 0.023-0.5; Bliss cumulative synergy volume range 0.13-234.32). In line with the in vitro findings, synergistic interactions were confirmed by in vivo experiments. The fungal kidney burden decreases were more than three log volumes in mice treated with combination of 1 mg/kg caspofungin and 20 mg/kg isavuconazole daily; this difference was statistically significant compared with control mice (P < 0.001). Despite the favorable effect of isavuconazole in combination with caspofungin, further studies are needed to confirm the therapeutic advantage of this combination when treating an infection caused by C. auris.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.